KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration

European Journal of Pharmacology

Volumn 754, Issue , 2015, Pages 179-189

  Watanabe, Yusuke ^a   Murata, Takahiko ^a   Amakawa, Masahiro ^a   Miyake, Yoshihide ^a   Handa, Tango ^a   Konishi, Katsuhiko ^b   Matsumura, Yasushi ^b   Tanaka, Takuji ^c   Takeuchi, Koji ^d  

^a KAKEN PHARMACEUTICAL CO LTD   (Japan)

^b ASAHI GLASS CO LTD   (Japan)

^c Gifu Municipal Hospital   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Colitis; Colorectal carcinogenesis; EP4 agonist; Mucosal healing; Orally available

Indexed keywords

3,3 DIFLUOROHEXAHYDRO 4 [3 HYDROXYL 4 (3 METHYLPHENYL) 1 PENTEN 1 YL] 2 [4 (1H TET RAZOL 5 YL)BUTYLIDENE] 2H CYCLOPENTA[B]FURAN 5 OL; 4 [1 [[[2,5 DIMETHYL 4 [4 (TRIFLUOROMETHYL)BENZYL] 3 THIENYL]CARBONYL]AMINO]CYCLOPROPYL]BENZOIC ACID; CD28 ANTIGEN; CD3 ANTIGEN; DEXTRAN SULFATE; MF 482; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AZOXYMETHANE; BENZOIC ACID DERIVATIVE; CYCLOPROPANE DERIVATIVE; KAG-308; MF-482; PROSTACYCLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD; CANCER INHIBITION; CD4+ T LYMPHOCYTE; COLON MALFORMATION; COLON MUCOSA; COLORECTAL CANCER; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG FATALITY; DRUG STRUCTURE; ENDOSCOPY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MICROSCOPY; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NORMAL HUMAN; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; RISK REDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCERATIVE COLITIS; WOUND HEALING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CELL CULTURE; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DRUG EFFECTS; INTESTINE MUCOSA; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; AZOXYMETHANE; BENZOATES; BIOLOGICAL AVAILABILITY; CELLS, CULTURED; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; CYCLOPROPANES; DEXTRAN SULFATE; EPOPROSTENOL; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTESTINAL MUCOSA; MICE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924567672     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.02.021     Document Type: Article

References (45)

1. Khan. A.K. Azad, J. Piris, and S.C. Truelove An experiment to determine the active therapeutic moiety of sulphasalazine Lancet 2 1977 892 895
2. C. Becker, M.C. Fantini, and M.F. Neurath High resolution colonoscopy in live mice Nat. Protoc. 1 2006 2900 2904
3. C. Becker, M.C. Fantini., S. Wirtz, A. Nikolaev, R. Kiesslich, H.A. Lehr, P.R. Galle, and M.F. Neurath In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy Gut 54 2005 950 954
4. A. Belley, and K. Chadee Prostaglandin E(2) stimulates rat and human colonic mucin exocytosis via the EP(4) receptor Gastroenterology 117 1999 1352 1362
5. C.N. Bernstein, Z. Nugent, and J.F. Blanchard 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study Am. J. Gastroenterol. 106 2011 731 736
6. 4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence Cancer Res. 66 2006 3106 3113
7. M.L. Clapper, M.A. Gary, R.A. Coudry, S. Litwin, W.C. Chang, K. Devarajan, R.A. Lubet, and H.S. Cooper 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis Inflamm. Bowel Dis. 14 2008 1341 1347
8. S. Ghosh, and R. Mitchell Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey J. Crohns. Colitis 1 2007 10 20
9. N. Harpaz, and I.C. Talbot Colorectal cancer in idiopathic inflammatory bowel disease Semin. Diagn. Pathol. 13 1996 339 357
10. R. Hatazawa, R. Ohno, M. Tanigami, A. Tanaka, and K. Takeuchi Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats J. Pharmacol. Exp. Ther. 318 2006 691 699
11. M.A. Hull, S.C. Ko, and G. Hawcroft Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol. Cancer Ther. 3 2004 1031 1039
12. M. Iacucci, and S. Ghosh Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease Ther. Adv. Gastroenterol. 4 2011 129 143
13. 4 receptor and indirectly through mesenchymal progenitor cells Blood 121 2013 1995 2007
14. Ishibashi, Y., Matsumura, Y., Shimazaki, A., Murata, T., 2014. Design, synthesis and development of novel fluorinated prostanoids as new therapeutic agents. In: Proceedings of the 4th International Symposium on Organofluorine Compounds, Bordeaux, France.
15. T.O. Ishikawa, and H.R. Herschman Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression Carcinogenesis 31 2010 729 736
16. 2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment J. Pharmacol. Exp. Ther. 335 2010 546 552
17. G.L. Jiang, A. Nieves, W.B. Im, D.W. Old, D.T. Dinh, and L. Wheeler The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration J. Pharmacol. Exp. Ther. 320 2007 22 28
18. 4 suppresses colitis, mucosal damage and CD4 cell activation in the gut J. Clin. Invest. 109 2002 883 893
19. 4 agonists Chem. Pharm. Bull. 59 2011 1523 1534
20. D.P. Kavanagh, A.I. Yemm, J.S. Alexander, J. Frampton, and N. Kalia Enhancing the adhesion of hematopoietic precursor cell integrins with hydrogen peroxide increases recruitment within murine gut Cell Transplant. 22 2013 1485 1499
21. 2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice J. Immunol. 170 2003 757 764
22. P. Munkholm Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease Aliment. Pharmacol. Ther. 18 2003 1 5
23. 4 agonist. US patent 8, 394, 844.
24. N.R. Murray, J. Weems, U. Braun, M. Leitges, and A.P. Fields Protein kinase C beta II and PKC iota/lambda: collaborating partners in colon cancer promotion and progression Cancer Res. 69 2009 656 662
25. M. Mutoh, K. Watanabe, T. Kitamura, Y. Shoji, M. Takahashi, T. Kawamori, K. Tani, M. Kobayashi, T. Maruyama, K. Kobayashi, S. Ohuchida, Y. Sugimoto, S. Narumiya, T. Sugimura, and K. Wakabayashi Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis Cancer Res. 62 2002 28 32
26. 4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial Inflamm. Bowel Dis. 16 2010 731 733
27. M.F. Neurath, and S.P. Travis Mucosal healing in inflammatory bowel diseases: a systematic review Gut 61 2012 1619 1635
28. O.H. Nielsen, and L.K. Munck Drug insight: aminosalicylates for the treatment of IBD Nat. Clin. Pract. Gastroenterol. Hepatol 4 2007 160 170
29. 2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329 Scand. J. Immunol. 56 2002 66 75
30. A. Northey, D. Denis, M. Cirino, K.M. Metters, and F. Nantel Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract Prostaglandins Other Lipid Mediat. 62 2000 145 156
31. 2 receptor subtype 4 agonist J. Pharmacol. Exp. Ther. 341 2012 340 349
32. M. Onizawa, T. Nagaishi, T. Kanai, K. Nagano, S. Oshima, Y. Nemoto, A. Yoshioka, T. Totsuka, R. Okamoto, T. Nakamura, N. Sakamoto, K. Tsuchiya, K. Aoki, K. Ohya, H. Yagita, and M. Watanabe Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis Am. J. Physiol. Gastrointest. Liver. Physiol. 296 2009 G850-859
33. Y.M. Petersen, B. Bjôrkenberg, K.N. Christjansen, M. Stalhut, H.D. Pedersen, and C. Thorkildsen Is the Murine Dextran Sodium Sulfate-Induced Colitis Model Valid for Predicting Drug Efficacy in IBD? 2009 Digestive Diseases Week Chicago, Illinois
34. 2 on proliferation of an intestinal goblet cell line and its synthesis and secretion of mucin glycoproteins Prostaglandins Leukot. Essent. Fatty Acids 48 1993 423 428
35. B.K. Popivanova, K. Kitamura, Y. Wu, T. Kondo, T. Kagaya, S. Kaneko, M. Oshima, C. Fujii, and N. Mukaida Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis J. Clin. Invest. 118 2008 560 570
36. A. Reinacher-Schick, F. Seidensticker, S. Petrasch, M. Reiser, S. Philippou, D. Theegarten, G. Freitag, and W. Schmiegel Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel Endoscopy 32 2000 245 254
37. K. Reinecke, S. Eminel, F. Dierck, W. Roessner, S. Kersting, A.M. Chromik, O. Gavrilova, A. Laukevicience, I. Leuschner, V. Waetzig, P. Rosenstiel, T. Herdegen, and C. Sina The JNK inhibitor XG-102 protects against TNBS-induced colitis PLoS One 7 2012 e30985
38. E.P. Serafini, A.P. Kirk, and T.J. Chambers Rate and pattern of epithelial cell proliferation in ulcerative colitis Gut 22 1981 648 652
39. D. Serra, J. Paixão, C. Nunes, T.C. Dinis, and L.M. Almeida. Cyanidin-3-glucoside suppresses cytokine-induced inflammatory response in human intestinal cells: comparison with 5-aminosalicylic acid PLoS One 8 2013 e73001
40. 2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis Eur. J. Pharmacol. 603 2009 120 132
41. W.N. Tindall, J.M. Boltri, and S.M. Wilhelm Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs J. Manag. Care Pharm. 13 2007 S2 S12
42. T.P. Van Staa, T. Card, R.F. Logan, and H.G.M. Leufkens 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study Gut 54 2005 1573 1578
43. J.M. Ward Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats Lab. Invest. 30 1974 505 513
44. L. Xu, Z.L. Yang, P. Li, and Y.Q. Zhou Modulating effect of Hesperidin on experimental murine colitis induced by dextran sulfate sodium Phytomedicine 16 2009 989 995
45. N. Yamaji, A. Ido, A. Moriuchi, M. Numata, H. Setoyama, T. Tamai, K. Funakawa, H. Fujita, T. Sakiyama, H. Uto, M. Oketani, and H. Tsubouchi Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice Oncol. Rep. 26 2011 335 341